- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00338923
Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.
This is a multicenter pilot study to assess the healing effects of HO/03/03 on diabetic neuropathic plantar and venous ulcers.
HO/03/03 action mechanism involves the manipulation of keratinocyte and fibroblast migration and differentiation at the wound area.
- The primary end point of this study is assessment of safety in treating with HO/03/03 and the efficacy of the drug to promote wound closure of chronic wounds.
- The secondary end points are assessment time to closure and healing rate for the measurement of wound healing progression.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter pilot study to assess the healing effects of HO/03/03 on diabetic neuropathic plantar and venous ulcers.
Pretreatment phase: During a pretreatment phase that will last up to 14 days, all patients will receive the conventional treatment once a day at the discretion of the investigator. All wounds will be morphologically monitored by photo documentation daily and measurements of wound area once a week.
Initial study visit: patients will begin treatment after completing all necessary demands in pre-treatment phase or after ruling out of all exclusion criteria. All wounds will be cleaned from previous treatment by surgical debridement and irrigation (saline).
Treatment phase: Following the pre-treatment phase, wounds will be treated topically with HO/03/03 for 30 days. During this 30 day phase, patients will receive daily treatments with HO/03/03 either at home by a certified nurse or at the clinic. Wounds will be monitored by certified medical staff member as well as photo documentation. Then application of the treatment followed by a 15-minute rest. Finally wound will be dressed with a fresh dressing and monitoring of any adverse events.
Patients will be administered HO/03/03 in addition to weight off-load Once a week wounds will be monitored by a physician: wounds size will be determined and documented. Patients will be evaluated for pain sensation at the wound area by filling a pain scoring questionnaire.
Twice during the experiment patients will undergo blood profile, HbA1c, blood glucose, and urine samples testing at the initial and terminating visits.
At the conclusion of the treatment phase the following will be completed:
- A physical examination;
- Collection of all blood and urine samples for clinical laboratory tests (dip sticks);
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Beer Yaakov, Israel, 70300
- Assaf Harofe Medical Center
-
Jerusalem, Israel
- Hadassah Ein Kerem Medical Center
-
Rechovot, Israel
- Kaplan Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must satisfy all of the following inclusion criteria to be included in the study:
- be male or female over the age of 18;
- have a diabetic neuropathic plantar and/or venous ulcer;
- wound diameter <10cm;
- wound depth is no more than exposed muscle;
- have a current physical examination, which reveals no clinically significant abnormalities, except diabetes or diabetic ulcer/wound related condition
- be available for the entire study period, and be able and willing to adhere to protocol requirements;
- vascular inflow as measured by Doppler: ABI >= 0.7
- have a debilitating wound over a period of 1 month prior to the experiment;
- if female of childbearing potential, must be using a reliable form of birth control;
- provide written informed consent prior to admission into the study.
Exclusion Criteria:
Patients will be excluded from the study if they meet any of the following exclusion criteria:
- have a body mass index (BMI) > 45;
- have a glycosylated hemoglobin (HbAlc) > 12.0%;
- have a history or presence of HIV or a clinically significant cardiac, gastrointestinal, endocrine, neurological, liver, or kidney disease;
- have any clinically significant illness during the 4 weeks prior to admission into the study, except diabetes type1 or type2;
- patients on concomitant medications that alter blood glucose levels (e.g., ACE inhibitors, lipid lowering agents, etc) must be on a stable dosage regimen for at least 4 weeks prior to entry into the study and the dosage must remain stable throughout the study;
- patients on chemotherapy;
- participation in a clinical study or use of an investigational drug within 30 days prior to admission to this study;
- are pregnant or lactating;
- visible bone exposure at wound site;
- have any signs of clinical infection in the wound (which could be linked to raised body temperature), necrosis, erythema or mild drainage;
- have any acute illness within 2 weeks prior to Screening;
- residing in a nursing facility and/or are bed-ridden (unable to come to receive treatment at the clinic);
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment arm
One Arm - Active Compound (HO/03/03)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety
Time Frame: Treatment Period
|
Treatment Period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to Heal & Rate of Healing
Time Frame: Treatment Period
|
Treatment Period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Micha Rapoport, Dr., Assaf Harofe Medical Center
- Principal Investigator: Leon Gilead, Dr., Hadassah Ein Kerem Medical Center
- Principal Investigator: Zvi Landau, Dr., Kaplan Medical Center
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HO-01-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
Clinical Trials on HO/03/03
-
HealOrCato Research; Clinigene International LtdUnknownDiabetic Foot UlcerUnited States, India
-
HealOrUnknownHard to Heal WoundsIsrael
-
Anhui Provincial HospitalNot yet recruitingB Lymphoblastic Leukemia/LymphomaChina
-
Tarsus Pharmaceuticals, Inc.CompletedBlepharitisUnited States
-
Cosmo Technologies LtdRecruitingAdvanced Refractory Solid Tumors | Subjects Considered Likely to Respond to CB-03-10United States
-
Enterin Inc.RecruitingObesity | Diabetes Mellitus, Type 2United States
-
1200 Pharma, LLCTranslational Research in OncologyRecruitingAdvanced Solid TumorUnited States
-
Kangen Pharmaceuticals, IncCompletedChronic PancreatitisUnited States, Russian Federation, Ukraine
-
Balgrist University HospitalCompletedPosttraumatic or Congenital Bone DeformitySwitzerland